- Home
- KLXE vs BCAB Comparison
KLXE vs BCAB Comparison
Compare KLXE & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLXE
- BCAB
- Stock Information
- Founded
- KLXE 2018
- BCAB 2007
- Country
- KLXE United States
- BCAB United States
- Employees
- KLXE N/A
- BCAB N/A
- Industry
- KLXE Oilfield Services/Equipment
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- KLXE Energy
- BCAB Health Care
- Exchange
- KLXE Nasdaq
- BCAB Nasdaq
- Market Cap
- KLXE 90.4M
- BCAB 96.2M
- IPO Year
- KLXE N/A
- BCAB 2020
- Fundamental
- Price
- KLXE $4.51
- BCAB $2.08
- Analyst Decision
- KLXE Hold
- BCAB Strong Buy
- Analyst Count
- KLXE 1
- BCAB 2
- Target Price
- KLXE $4.50
- BCAB $6.00
- AVG Volume (30 Days)
- KLXE 92.5K
- BCAB 1.6M
- Earning Date
- KLXE 11-04-2024
- BCAB 11-08-2024
- Dividend Yield
- KLXE N/A
- BCAB N/A
- EPS Growth
- KLXE N/A
- BCAB N/A
- EPS
- KLXE N/A
- BCAB N/A
- Revenue
- KLXE $769,700,000.00
- BCAB N/A
- Revenue This Year
- KLXE N/A
- BCAB N/A
- Revenue Next Year
- KLXE $3.17
- BCAB N/A
- P/E Ratio
- KLXE N/A
- BCAB N/A
- Revenue Growth
- KLXE N/A
- BCAB N/A
- 52 Week Low
- KLXE $4.18
- BCAB $1.14
- 52 Week High
- KLXE $12.13
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- KLXE 33.44
- BCAB 55.80
- Support Level
- KLXE $4.31
- BCAB $1.87
- Resistance Level
- KLXE $4.59
- BCAB $2.13
- Average True Range (ATR)
- KLXE 0.31
- BCAB 0.12
- MACD
- KLXE -0.05
- BCAB 0.00
- Stochastic Oscillator
- KLXE 8.92
- BCAB 68.90
About KLXE KLX Energy Services Holdings Inc.
KLX Energy Services Holdings Inc is a provider of completion, intervention and production services and products to the onshore oil and gas producing regions of the United States. It serves the companies engaged in the exploration and development of onshore conventional and unconventional oil and natural gas reserves. Its products and services offerings include surface facilities and equipment, pressure control services, wireline services, fishing services, and engineered products. The company's segments include Southwest; Rocky Mountains and Northeast/Mid-Con region. It derives maximum revenue from Northeast/Mid-Con region.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.